Pneumonia Severity Assessment: CURB-65 versus PSI in Predicting Admission Need and Mortality — A Prospective Comparative Study
DOI:
https://doi.org/10.48165/ajm.2026.9.01.5Keywords:
community-acquired pneumonia; CURB-65; Pneumonia Severity Index; mortality prediction; hospital admission; severity assessment; prognostic scoringAbstract
Background: Community-acquired pneumonia (CAP) remains a leading cause of morbidity and mortality worldwide. Accurate severity assessment is crucial for determining appropriate disposition and treatment intensity. The CURB-65 and Pneumonia Severity Index (PSI) are widely utilized scoring systems, yet their comparative performance in diverse clinical settings continues to be debated. Methods: A prospective cohort study was conducted at two teaching hospitals over 24 months, enrolling 634 adult patients with confirmed CAP. Both CURB-65 and PSI scores were calculated at presentation. Primary outcomes included requirement for hospital admission and 30-day all-cause mortality. Receiver operating characteristic (ROC) curve analysis and comparative statistics were performed. Results: The mean age was 62.7 ± 18.4 years, with 56.8% male patients. Hospital admission was required in 412 patients (65.0%), and 30-day mortality occurred in 58 patients (9.1%). For mortality prediction, PSI demonstrated an AUC of 0.842 (95% CI: 0.798– 0.886) compared to 0.814 (95% CI: 0.766–0.862) for CURB-65 (p=0.089). For predicting admission need, PSI showed superior discrimination (AUC 0.812 vs. 0.758, p=0.012). PSI risk class IV-V had 87.9% sensitivity and 72.4% specificity for mortality, while CURB-65 ≥3 showed 79.3% sensitivity and 78.6% specificity. Conclusion: Both scoring systems demonstrate good predictive accuracy for mortality in CAP patients. PSI shows superior performance for determining admission need, while CURB-65 offers comparable mortality prediction with greater simplicity. Clinical context should guide score selection.References
Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427. doi:10.1056/NEJMoa1500245
Wunderink RG, Waterer GW. Community-acquired pneumonia. N Engl J Med. 2014;370(6):543-551. doi:10.1056/NEJMcp1214869
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-S72. doi:10.1086/511159
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST
Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 2000;283(6):749-755. doi:10.1001/jama.283.6.749
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. doi:10.1056/NEJM199701233360402
Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005;118(4):384-392. doi:10.1016/j.amjmed.2005.01.006
Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community-acquired pneumonia. Thorax. 2004;59(5):421-427. doi:10.1136/thx.2003.008110
Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax. 2003;58(5):377-382. doi:10.1136/thorax.58.5.377
Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community-acquired pneumonia in adults: Update 2009. Thorax. 2009;64(Suppl 3):iii1-iii55. doi:10.1136/thx.2009.121434
Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia: Systematic review and meta-analysis. Thorax. 2010;65(10):878-883. doi:10.1136/thx.2009.133280
Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: A randomized, controlled trial. Ann Intern Med. 2005;143(12):881-894. doi:10.7326/0003-4819-143-12-200512200-00006
Capelastegui A, España PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006;27(1):151-157. doi:10.1183/09031936.06.00062505
Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: A systematic review and meta-analysis. Crit Care. 2012;16(4):R141. doi:10.1186/cc11447
Phua J, See KC, Chan YH, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. 2009;64(7):598-603. doi:10.1136/thx.2009.113795
Renaud B, Coma E, Labarere J, et al. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: A multicenter, prospective, observational, controlled cohort study. Clin Infect Dis. 2007;44(1):41-49. doi:10.1086/509427
Menéndez R, Martinez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64(7):587-591. doi:10.1136/thx.2008.105312
Loke YK, Kwok CS, Niruban A, et al. Value of severity scales in predicting mortality from community-acquired pneumonia: Systematic review and meta-analysis. Thorax. 2010;65(10):884-890. doi:10.1136/thx.2009.134072

